Clinical Edge Journal Scan

Early menopause worsens disease outcomes in postmenopausal women with RA


 

Key clinical point: Menopause at an early vs usual age ( <45 vs 45 years) was associated with a higher disease activity and worse patient-reported outcomes in postmenopausal women with rheumatoid arthritis (RA).

Major finding: At baseline, women with early vs usual menopause had significantly higher Disease Activity Score in 28 joints (DAS28; P = .018) and Visual Analogue Scale (VAS) scores for global assessment ( P = .016) and fatigue ( P = .005), along with worse EuroQol-5D-VAS scores ( P = .006). Early menopause was significantly associated with increased DAS28 (regression coefficient [ β] 0.178; P = .013) and decreased EuroQol-5D utility values ( β −0.033; P = .016) at 5-year follow-up.

Study details: This prospective observational cohort study included 2878 postmenopausal women with RA who had menopause at an early (n = 437) or usual (n = 2441) age.

Disclosures: This study was supported by Chung-Ang University research grants in 2022 and the National Research Foundation of Korea grant funded by the Korean government. The authors did not declare conflicts of interest.

Source: Park EH et al. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: A large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open . 2023;9:e002722 (Feb 15). Doi: 10.1136/rmdopen-2022-002722

Recommended Reading

FDA approves first biologic treatment for polymyalgia rheumatica
MDedge Rheumatology
Commentary: ILD and other issues in RA treatment, March 2023
MDedge Rheumatology
Call it preclinical or subclinical, ILD in RA needs to be tracked
MDedge Rheumatology
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
MDedge Rheumatology
New JAK inhibitor study data confirm benefit in alopecia areata
MDedge Rheumatology
Tofacitinib may have possible protective effect against ILD in RA
MDedge Rheumatology
Administering concomitant methotrexate at a half vs usual dose while initiating TNFi is feasible
MDedge Rheumatology
Higher disability at early stages raises risk for progression to difficult-to-treat RA
MDedge Rheumatology
RA raises risk for long-term MACE in patients undergoing percutaneous coronary intervention
MDedge Rheumatology
CT-based screening for malignancies may benefit patients with RA who initiated b/tsDMARD
MDedge Rheumatology